Eiger BioPharmaceuticals, Inc. Annual Operating Lease, Payments in USD from 2019 to 2022

Taxonomy & unit
us-gaap: USD
Description
Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.
Summary
Eiger BioPharmaceuticals, Inc. quarterly/annual Operating Lease, Payments history and growth rate from 2019 to 2022.
  • Eiger BioPharmaceuticals, Inc. Operating Lease, Payments for the quarter ending March 31, 2023 was $200K, unchanged year-over-year.
  • Eiger BioPharmaceuticals, Inc. annual Operating Lease, Payments for 2022 was $700K, a 16.7% increase from 2021.
  • Eiger BioPharmaceuticals, Inc. annual Operating Lease, Payments for 2021 was $600K, a 14.3% decline from 2020.
  • Eiger BioPharmaceuticals, Inc. annual Operating Lease, Payments for 2020 was $700K, a 16.7% increase from 2019.
Operating Lease, Payments, Annual (USD)
Operating Lease, Payments, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2022 $700K +$100K +16.7% Jan 1, 2022 Dec 31, 2022 10-K 2023-03-17
2021 $600K -$100K -14.3% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-17
2020 $700K +$100K +16.7% Jan 1, 2020 Dec 31, 2020 10-K 2023-03-17
2019 $600K Jan 1, 2019 Dec 31, 2019 10-K 2022-03-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.